Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERCE II: Regorafenib Sequencing in mCRC
NCT04117945Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Academic and Community Cancer Research United. Started Mar 2020; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04117945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117945.